Table 3.
Regression analysis for secondary outcomes.
| Outcomes | Crude analysis |
P-valuef | Odds Ratio (OR) (95% CI) | P-valueg | |
|---|---|---|---|---|---|
| Single-dose | Multiple-dose | ||||
| Respiratory Failure Required MV, n (%)b | 8/18 (44.4) | 7/20 (35.0) | 0.55 | 0.78 (0.20, 2.99) | 0.71 |
| AKI during ICU stay, n (%)a | 26/64 (40.6) | 22/64 (34.4) | 0.46 | 0.73 (0.35, 1.52) | 0.40 |
| Liver Injury during ICU stay, n (%)a | 4/64 (6.3) | 6/64 (9.4) | 0.51 | 1.46 (0.38, 5.62) | 0.58 |
| Thrombosis during ICU stay, n (%)a | 7/64 (10.9) | 5/64 (7.81) | 0.54 | 0.62 (0.17, 2.16) | 0.45 |
| Secondary infectiona | |||||
| Hospital/Ventilator Acquired Pneumonia, n (%) | 18/64 (28.1) | 39/64 (60.9) | 0.0002 | 3.81 (1.79, 8.12) | 0.0005 |
| Bacteremia, n (%) | 5/64 (7.81) | 8/64 (12.5) | 0.38 | 1.78 (0.54, 5.86) | 0.35 |
| Urinary tract infection, n (%) | 3/61 (4.7) | 3/61 (4.7) | >0.99 | 0.97 (0.18, 5.2) | 0.97 |
| Single-dose | Multiple-dose | P-valuee | beta coefficient (Estimates) (95% CI) | P-valueh | |
| MV duration during ICU stay (Days), Median (Q1,Q3)c | 8.5 (4.5, 16.0) | 12.0 (7.0, 18.0) | 0.14 | 0.25 (−0.06, 0.55) | 0.11 |
| ICU Length of Stay (Days), Median (Q1,Q3)d | 9.5 (8.0, 23.0) | 10.0 (7.0, 17.0) | 0.87 | 0.12 (−0.22, 0.45) | 0.49 |
| Hospital Length of Stay (Days), Median (Q1,Q3)d | 19.5 (11.0, 31.0) | 19.0 (13.0, 24.0) | 0.96 | 0.09 (−0.24, 0.42) | 0.58 |
a
Denominator of the percentage is the total number of patients.
b
Denominator of the percentage is non-mechanically ventilated patients with 24 h of ICU admission.
c
Denominator is patients who have respiratory failure required MV.
d
Denominator is patients who survived.
e
Wilcoxon rank sum test is used to calculate the P-value.
f
Chi-square test is used to calculate the P-value.
g
Multivariate Logistic regression is used to calculate Odds ratio and p-value.
h
Generalized linear model is to calculate beta coefficient (estimates) and p-value.